Skip to main content

Table 3 Study characteristics and results of risk factors for acquiring P. aeruginosa

From: Pseudomonas infections among hospitalized adults in Latin America: a systematic review and meta-analysis

Author YearCountry (Enrollment Period)Study DesignHospital SettingType of FundingTotal NSite of InfectionSource of infectionCase / ExposureControl / comparatorMean Age yr% Male
Araujo 2016 [12]Brazil (2009–2012; 2014)CCAcademicGov236Bacteremia 100%Nosocomial and Community-acquiredMDR-PANon-MDR PA52.770.3
Cortes 2009 [22]Colombia (2001–2002)CCGovNR96Operation site 31%,
RS 31%, BSI 50%
NosocomialMDR-PARandom patients hospitalized the same day43.551
DalBen 2013 [23]Brazil (2000–2002)PCTertiaryGov; Academic325NRNosocomialCRPANA4441
Dantas 2014 [15]Brazil (2009–2011)RCAcademicGov120BSI 100%NRResistant,MDR-PA and XDR-PANA51.563.3
Fortaleza 2006 (Study 1) [25]Brazil (1992–2002)CCAcademicNR324Wound 21.3%, BSI 19.4%, UTI 16.7%NosocomialIRPA or Ceftazidine-resistant PAPatients without IRPA who were admitted to the same ward44.363
Fortaleza 2006 (Study 2) [25]Brazil (1992–2002)CCAcademicNR165UTI 27.3%, RS 25.5%, wounds 21.8%,NRIRPA or Ceftazidine-resistant PAPatients without IRPA who were admitted to the same ward42.366
Furtado 2009 [28]Brazil (2003–2004)CCAcademicNR245UTI 34.9%; RS 22.2%; catheter tip 20.6%NosocomialIRPAPatients hospitalized in the same unit and matched to case patientsMedian: Cases: 50, Controls: 5461.6
Furtado 2010 [24]Brazil (2006–2008)CCAcademicNR295RS 100%NosocomialIRPAPatients without PA receiving care in same ICU5459.3
Gomes 2012 [30]Brazil (2002–2007)PCCTertiaryGov60NRNosocomialMDR-PAControlsMedian: Cases: 50, Controls: 4066.7
Medell 2012 [29]Cuba (2011)PCTertiaryGov12VAP 100%NosocomialPANA55.5NR
Neves 2010 [18]Brazil (2004–2005)Ecological design; RCAcademicNR350NRNRMDR-PANANRNR
Ossa-Giraldo 2014 [19]Colombia (2009–2010)CCAcademicUniversity Hospital140NRNosocomialMDR-PASusceptible PA43.370
Pereira 2008 [27]Brazil (2000–2002)CCAcademicAcademic59UTI 60%, BSI 7%, RS 17%NosocomialIRPAISPA51.362.7
Rossi 2017 [14]Brazil (2009–2012)CCAcademicUniversity Hospital157Unknown: 62.42; RS: 17.19; BSI: 13.37NosocomialCRPACSPA66.931.2
Royer 2015 [21]Brazil (2011–2012)PCAcademicGov30VAP 100%NosocomialCRPANA58.9780
Tuon 2012 [16]Brazil (2006–2009)CCTertiaryNR77BSI 100%NosocomialCRPACSPA47.423.7
Valderrama 2016 [20]Colombia (2008–2014)CCAcademicUniversity Hospital168RS 30%; GI 26%; Primary 13.7%NosocomialCRPACSPACases: 60; Controls: 64.553
Zavascki 2005 (Study1) [26]Brazil (2002–2003)CCTertiaryGov186IRPA:RS 33.4%, UTI 26.9%, Control: NRNosocomialIRPARandom patients from same unit54.556.5
Zavascki 2005 (Study2) [26]Brazil (2002–2003)CCTertiaryGov158IRPA: RS 33.4%, UTI 26.9%, Control: NRNosocomialIRPAISPA54.762.7
  1. BSI Bacteremia; CC Case-control; CRPA Carbapenem resistant Pseudomonas aeruginosa; CSPA Carbapenem susceptible Pseudomonas aeruginosa; Gov Government; GI Gastrointestinal; IRPA imipenem-resistant Pseudomonas aeruginosa; ISPA imipenem- susceptible Pseudomonas aeruginosa; MDR Multi-drug resistant; N Number; NA Not applicable; NR Not reported; PA Pseudomonas aeruginosa; PC Prospective; PCC Prospective case-control; RC Retrospective; RS Respiratory; UTI Urinary tract infection; VAP ventilator-associated pneumonia; XDR Extreme drug resistant; Yr year